Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

222
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
222
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

1.5K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.5K
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

8.1K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
8.1K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

1.9K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.9K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

389
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
389
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

379
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
379

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Protein expression and significance of VEGF, EGFR and MMP-9 in non-small cell lung carcinomas.

Asian Pacific journal of cancer prevention : APJCP·2011
Same author

Bilirubin attenuates bufadienolide-induced ventricular arrhythmias and cardiac dysfunction in guinea-pigs by reducing elevated intracellular Na(+) levels.

Cardiovascular toxicology·2011
Same author

Parental knowledge regarding lifelong congenital cardiac care.

Pediatrics·2011
Same author

RING domain mutations uncouple TRIM5α restriction of HIV-1 from inhibition of reverse transcription and acceleration of uncoating.

Journal of virology·2011
Same author

Applied force provides insight into transcriptional pausing and its modulation by transcription factor NusA.

Molecular cell·2011
Same author

[Remote monitoring of home-based noninvasive ventilation in children with obstructive sleep apnea-hypopnea syndrome and concomitant risk factors].

Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery·2011
Same journal

Isavuconazole for invasive mold disease in patients with hematological malignancies: a multicenter real-world study from China on efficacy, safety, and competing risks.

Antimicrobial agents and chemotherapy·2026
Same journal

An Achilles' heel for methicillin-resistant <i>Staphylococcus aureus</i>? Re-evaluating β-lactam susceptibility of MRSA.

Antimicrobial agents and chemotherapy·2026
Same journal

Essential role of glycogen synthase kinase 3 in regulating growth, drug response, and infectivity in <i>Leishmania infantum</i>.

Antimicrobial agents and chemotherapy·2026
Same journal

<i>In vitro</i> antibacterial activity of gepotidacin in combination with other antimicrobial agents against <i>Neisseria gonorrhoeae</i> isolates.

Antimicrobial agents and chemotherapy·2026
Same journal

Development of domain-specific probes of <i>Plasmodium falciparum</i> heat shock protein 70-1.

Antimicrobial agents and chemotherapy·2026
Same journal

Addressing therapeutic options for KPC-3-producing ST307-<i>Klebsiella pneumoniae</i>: insights from <i>in vitro</i> evolution and mutant prevention strategies.

Antimicrobial agents and chemotherapy·2026
See all related articles

Related Experiment Video

Updated: Dec 27, 2025

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.4K

Tigecycline treatment causes a decrease in fibrinogen levels.

Qian Zhang1, Suming Zhou1, Jing Zhou2

  • 1Department of Geriatrics Intensive Care Unit, the First Affiliated Hospital of Nanjing Medical University, Nanjing, People's Republic of China.

Antimicrobial Agents and Chemotherapy
|December 31, 2014
PubMed
Summary
This summary is machine-generated.

Tigecycline treatment for severe infections significantly lowers fibrinogen (FIB) levels, with higher doses causing a greater reduction. Coagulation times like prothrombin time (PT) and activated partial thromboplastin time (APTT) also prolonged during treatment.

More Related Videos

Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization
06:28

Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization

Published on: June 4, 2020

7.1K
Analysis of &#946;-Amyloid-induced Abnormalities on Fibrin Clot Structure by Spectroscopy and Scanning Electron Microscopy
06:27

Analysis of β-Amyloid-induced Abnormalities on Fibrin Clot Structure by Spectroscopy and Scanning Electron Microscopy

Published on: November 30, 2018

9.6K

Related Experiment Videos

Last Updated: Dec 27, 2025

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.4K
Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization
06:28

Leveraging Turbidity and Thromboelastography for Complementary Clot Characterization

Published on: June 4, 2020

7.1K
Analysis of &#946;-Amyloid-induced Abnormalities on Fibrin Clot Structure by Spectroscopy and Scanning Electron Microscopy
06:27

Analysis of β-Amyloid-induced Abnormalities on Fibrin Clot Structure by Spectroscopy and Scanning Electron Microscopy

Published on: November 30, 2018

9.6K

Area of Science:

  • Pharmacology
  • Hematology
  • Infectious Diseases

Background:

  • Severe infections pose significant clinical challenges.
  • Tigecycline is a broad-spectrum antibiotic used for complex infections.
  • The impact of tigecycline on coagulation parameters requires further elucidation.

Purpose of the Study:

  • To evaluate the effect of tigecycline on fibrinogen (FIB) levels in patients with severe infections.
  • To assess changes in other coagulation markers, including prothrombin time (PT), activated partial thromboplastin time (APTT), and thrombin time (TT).
  • To monitor renal and liver function during tigecycline therapy.

Main Methods:

  • A cohort of 20 patients with severe infections treated with tigecycline was studied.
  • Coagulation parameters (FIB, PT, APTT, TT) and markers of renal and liver function were measured before, during, and after treatment.
  • Patients received either the recommended or a higher dose of tigecycline.

Main Results:

  • Tigecycline treatment led to a significant decrease in fibrinogen (FIB) levels, which normalized post-treatment.
  • Higher tigecycline doses resulted in a more pronounced reduction in FIB levels.
  • Prothrombin time (PT), activated partial thromboplastin time (APTT), and thrombin time (TT) were prolonged during treatment, with TT normalizing post-treatment.
  • No significant changes were observed in platelet counts, ALT, or creatinine levels.

Conclusions:

  • Tigecycline use is associated with a significant decrease in fibrinogen (FIB) levels in patients with severe infections.
  • The reduction in FIB is dose-dependent and reversible upon treatment cessation.
  • Tigecycline can prolong coagulation times (PT, APTT, TT), necessitating careful monitoring in at-risk patients.